Marker Therapeutics (NASDAQ:MRKR) Now Covered by LADENBURG THALM/SH SH

LADENBURG THALM/SH SH initiated coverage on shares of Marker Therapeutics (NASDAQ:MRKR) in a report issued on Tuesday, Benzinga reports. The firm set a “buy” rating and a $11.00 price target on the stock. LADENBURG THALM/SH SH’s price target would indicate a potential upside of 167.64% from the stock’s current price.

Marker Therapeutics Stock Performance

Shares of NASDAQ MRKR opened at $4.11 on Tuesday. The business has a 50-day moving average of $4.28 and a 200-day moving average of $3.98. Marker Therapeutics has a fifty-two week low of $0.95 and a fifty-two week high of $9.68.

Institutional Investors Weigh In On Marker Therapeutics

An institutional investor recently raised its position in Marker Therapeutics stock. International Assets Investment Management LLC boosted its position in Marker Therapeutics, Inc. (NASDAQ:MRKR) by 1,000.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 11,000 shares of the company’s stock after purchasing an additional 10,000 shares during the period. International Assets Investment Management LLC owned about 0.12% of Marker Therapeutics worth $60,000 as of its most recent filing with the SEC. Institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells.